Artiva Biotherapeutics, Inc. is a clinical-stage biotechnology company dedicated to developing and commercializing off-the-shelf, allogeneic natural killer (NK) cell therapies to treat cancer. Their mission is to harness the power of the innate immune system to provide more effective and accessible cancer treatments. Artiva is advancing a pipeline of NK cell therapies, including AlloNK® (AB-101) and CAR-NK candidates like AB-201, designed to be readily available for patients and overcome limitations of autologous cell therapies.
The headquarters serves as the central hub for Artiva's research and development, clinical operations, corporate strategy, and administrative functions, driving the company's mission to develop novel NK cell therapies.
Located within a modern biotech park, the facility likely includes state-of-the-art laboratory spaces for cell therapy research, process development, and quality control, alongside corporate offices.
Artiva fosters a highly collaborative, innovative, and science-driven work culture. The environment is focused on advancing cutting-edge therapies with a strong sense of urgency, teamwork, and a patient-centric mission.
The San Diego headquarters is strategically positioned within a vibrant ecosystem of world-class research institutions, numerous biotech companies, and a rich talent pool, facilitating collaborations and accelerating innovation in cancer immunotherapy.
While Artiva Biotherapeutics is headquartered in the United States, it maintains a significant global dimension through strategic partnerships, most notably with GC Cell in South Korea for the development, manufacturing, and commercialization of its NK cell therapies in Asia. The company's clinical trials are often designed for international participation to reach diverse patient populations, and its investor base includes international entities, reflecting its global outlook in addressing cancer.
9310 Athena Circle, Suite 200
La Jolla
CA
USA
Highperformr Signals uncover buying intent and give you clear insights to target the right accounts at the right time — helping your sales, marketing, and GTM teams close more deals, faster.
As of April 2025, Artiva Biotherapeutics' leadership includes:
Artiva Biotherapeutics has been backed by several prominent investors over the years, including:
Over the past 12 months, Artiva Biotherapeutics has significantly strengthened its leadership team with key appointments in finance, development, and human resources, underscoring its commitment to growth and advancing its clinical pipeline. No notable executive departures were publicly announced during this period.
Discover the tools Artiva Biotherapeutics uses. Highperformr reveals the technologies powering your target accounts — helping your sales, marketing, and GTM teams prioritize smarter and close faster.
While Artiva Biotherapeutics does not publicly disclose its specific email format structure, a common pattern observed in many biotechnology companies is the [first_initial][last]@[companydomain.com] format. Other possibilities include [first].[last]@[companydomain.com].
[first_initial][last]@artivabio.com
Format
jdoe@artivabio.com
Example
75%
Success rate
Artiva Biotherapeutics Website (via PR Newswire) • January 8, 2024
Artiva Biotherapeutics announced the appointment of Sarah McCabe as its new Chief Financial Officer. Ms. McCabe brings over 20 years of financial leadership experience in the biopharmaceutical industry to Artiva....more
Artiva Biotherapeutics Website (via PR Newswire) • December 11, 2023
Artiva shared encouraging updated clinical data from its Phase 1/2 study of AlloNK® (AB-101), an allogeneic NK cell therapy, in combination with rituximab for patients with relapsed/refractory B-cell non-Hodgkin lymphoma. The data highlighted positive efficacy and safety profiles....more
Artiva Biotherapeutics Website (via PR Newswire) • August 2, 2023
Artiva announced significant additions to its executive team with Ahmad Termechi, Ph.D., joining as Chief Development Officer and Jennifer Bush as Chief People Officer, aiming to bolster the company's development capabilities and human resources functions....more
See where a company’s workforce is located, by country or region.
View past and recent funding rounds with amounts and investors.
Understand company revenue estimates and financial scale.
Track active roles and hiring trends to spot growth signals.
Discover what a company offers—products, platforms, and solutions.
Get the company’s official SIC and NAICS classifications.
Analyze visitor volume, engagement, and top traffic sources.
Explore LinkedIn, Twitter, and other active social profiles.
Identify top competitors based on similar business traits.
Explore companies in depth — from the tech they use to recent funding, hiring trends, and buyer signals — all in one powerful view.
Highperformr AI helps you surface the right accounts and enrich your CRM with verified company and contact insights, so your teams can prioritize and engage faster.
Thousands of companies, including Artiva Biotherapeutics, are just a search away.